Ho A K, Young I, Chik C L
Department of Physiology, Faculty of Medicine, University of Alberta, Edmonton, Canada.
Biochem Pharmacol. 1991;41(6-7):897-903. doi: 10.1016/0006-2952(91)90194-a.
In rat pinealocytes, norepinephrine (NE) increases cAMP and cGMP accumulation through a synergistic dual receptor mechanism involving alpha 1- and beta-adrenergic receptors. The available evidence indicates that both increases in intracellular Ca2+ ([Ca2+]i, and activation of protein kinase C are involved in the alpha 1-adrenergic potentiation of beta-adrenergically stimulated cAMP and cGMP responses. In this study, the role of Ca2+ was further investigated using three agents with known anti-calmodulin activities: trifluoperazine, pimozide and W7. It was found that none of these inhibitors had any effects on the isoproterenol (ISO)-stimulated cAMP and cGMP responses. By contrast, all three Ca2+/calmodulin inhibitors reduced the NE-stimulated cAMP and cGMP responses. These results suggested that an alpha 1-adrenergic mediated mechanism was likely sensitive to the inhibitory action of the Ca2+/calmodulin inhibitors. To determine the possible site of action of the inhibitors, an activator of protein kinase C, 4 beta-phorbol 12-myristate 13-acetate (PMA), was used to potentiate the ISO-stimulated cAMP response. The PMA potentiation of ISO-stimulated cAMP response was only inhibited by a high concentration of pimozide, and not by trifluoperazine or W7, suggesting that pimozide may have other actions distinct from those of trifluoperazine or W7. Full potentiation of the cGMP response can be achieved by adding both PMA and a depolarizing concentration of K+. All three calmodulin antagonists were effective in inhibiting the PMA and K+ potentiation of cGMP responses in ISO-stimulated cells. These three compounds were also effective in inhibiting the potentiating effects of [Ca2+]i elevating agents on the beta-adrenergically stimulated cAMP and cGMP responses. The three inhibitors, at the concentrations used in the present study, were found to have no effect on the protein kinase C activity determined in vitro. These results indicated that apart from the protein kinase C pathway, the Ca2+/calmodulin pathway of signal transduction may be of importance in the regulation of pinealocyte cGMP and, to a lesser degree, cAMP responses.
在大鼠松果体细胞中,去甲肾上腺素(NE)通过涉及α1 - 和β - 肾上腺素能受体的协同双受体机制增加环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)的积累。现有证据表明,细胞内钙离子浓度([Ca2 +]i)的升高和蛋白激酶C的激活均参与α1 - 肾上腺素能对β - 肾上腺素能刺激的cAMP和cGMP反应的增强作用。在本研究中,使用三种已知具有抗钙调蛋白活性的药物:三氟拉嗪、匹莫齐特和W7,进一步研究了钙离子的作用。发现这些抑制剂均对异丙肾上腺素(ISO)刺激的cAMP和cGMP反应无任何影响。相比之下,所有三种Ca2 + /钙调蛋白抑制剂均降低了NE刺激的cAMP和cGMP反应。这些结果表明,α1 - 肾上腺素能介导的机制可能对Ca2 + /钙调蛋白抑制剂的抑制作用敏感。为了确定抑制剂的可能作用位点,使用蛋白激酶C激活剂4β - 佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)来增强ISO刺激的cAMP反应。PMA对ISO刺激的cAMP反应的增强作用仅被高浓度的匹莫齐特抑制,而不被三氟拉嗪或W7抑制,这表明匹莫齐特可能具有与三氟拉嗪或W7不同的其他作用。通过添加PMA和去极化浓度的钾离子(K +),可以实现cGMP反应的完全增强。所有三种钙调蛋白拮抗剂均能有效抑制ISO刺激细胞中PMA和K +对cGMP反应的增强作用。这三种化合物也能有效抑制[Ca2 +]i升高剂对β - 肾上腺素能刺激的cAMP和cGMP反应的增强作用。在本研究中使用的浓度下,发现这三种抑制剂对体外测定的蛋白激酶C活性无影响。这些结果表明,除了蛋白激酶C途径外,信号转导的Ca2 + /钙调蛋白途径可能在松果体细胞cGMP的调节中起重要作用,并且在较小程度上对cAMP反应也有作用。